Next Article in Journal
Post-Harvest Contamination with Mycotoxins in the Context of the Geographic and Agroclimatic Conditions in Romania
Previous Article in Journal
Spatiotemporal Gait Analysis and Lower Limb Functioning in Foot Dystonia Treated with Botulinum Toxin
Concept Paper

Biosynthetic Oligoclonal Antivenom (BOA) for Snakebite and Next-Generation Treatments for Snakebite Victims †

1
Department of Biological Sciences, National University of Singapore, 14 Science Drive 4, Singapore 117543, Singapore
2
Department of Molecular Genetics, The Donnelly Centre, University of Toronto, 160 College Street, Toronto, ON M5S 3E1, Canada
3
Department of Biotechnology and Biomedicine, Technical University of Denmark, DK-2800 Kongens Lyngby, Denmark
*
Author to whom correspondence should be addressed.
This concept paper summarizes the key discussions at the Live and Let Live: Snakebite Cure Symposium at the Nextgen Genomics, Biology, Bioinformatics and Technologies Conference in Jaipur, India, October 2018.
Toxins 2018, 10(12), 534; https://doi.org/10.3390/toxins10120534
Received: 23 October 2018 / Revised: 6 December 2018 / Accepted: 10 December 2018 / Published: 13 December 2018
Snakebite envenoming is a neglected tropical disease that each year claims the lives of 80,000–140,000 victims worldwide. The only effective treatment against envenoming involves intravenous administration of antivenoms that comprise antibodies that have been isolated from the plasma of immunized animals, typically horses. The drawbacks of such conventional horse-derived antivenoms include their propensity for causing allergenic adverse reactions due to their heterologous and foreign nature, an inability to effectively neutralize toxins in distal tissue, a low content of toxin-neutralizing antibodies, and a complex manufacturing process that is dependent on husbandry and procurement of snake venoms. In recent years, an opportunity to develop a fundamentally novel type of antivenom has presented itself. By using modern antibody discovery strategies, such as phage display selection, and repurposing small molecule enzyme inhibitors, next-generation antivenoms that obviate the drawbacks of existing plasma-derived antivenoms could be developed. This article describes the conceptualization of a novel therapeutic development strategy for biosynthetic oligoclonal antivenom (BOA) for snakebites based on recombinantly expressed oligoclonal mixtures of human monoclonal antibodies, possibly combined with repurposed small molecule enzyme inhibitors. View Full-Text
Keywords: snakebite envenoming; neglected tropical diseases; antivenom; next-generation antivenom; recombinant antivenom; small molecule inhibitors snakebite envenoming; neglected tropical diseases; antivenom; next-generation antivenom; recombinant antivenom; small molecule inhibitors
Show Figures

Figure 1

MDPI and ACS Style

Kini, R.M.; Sidhu, S.S.; Laustsen, A.H. Biosynthetic Oligoclonal Antivenom (BOA) for Snakebite and Next-Generation Treatments for Snakebite Victims. Toxins 2018, 10, 534. https://doi.org/10.3390/toxins10120534

AMA Style

Kini RM, Sidhu SS, Laustsen AH. Biosynthetic Oligoclonal Antivenom (BOA) for Snakebite and Next-Generation Treatments for Snakebite Victims. Toxins. 2018; 10(12):534. https://doi.org/10.3390/toxins10120534

Chicago/Turabian Style

Kini, R. M., Sachdev S. Sidhu, and Andreas H. Laustsen. 2018. "Biosynthetic Oligoclonal Antivenom (BOA) for Snakebite and Next-Generation Treatments for Snakebite Victims" Toxins 10, no. 12: 534. https://doi.org/10.3390/toxins10120534

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop